Staidson Beijing Biopharma (300204) — Cash Flow Quality Index
Staidson Beijing Biopharma (300204) has a Cash Flow Quality Index of -15.09x as of June 2024. Operating cash flow of CN¥-5.23 Million is below net income of CN¥346.39K, suggesting accrual-heavy earnings not yet converted to cash. Explore Staidson Beijing Biopharma cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Staidson Beijing Biopharma Cash Flow Quality Index (2008–2019)
Historical Cash Flow Quality Index for Staidson Beijing Biopharma across 12 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Staidson Beijing Biopharma investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Staidson Beijing Biopharma (2008–2019)
Year-by-year earnings quality comparison for Staidson Beijing Biopharma. For live market cap and the full company financial profile, see 300204 company net worth.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2019 | 1.62x | CN¥44.34 Million | CN¥27.30 Million | ▲ +31.9% |
| 2018 | 1.23x | CN¥165.08 Million | CN¥134.06 Million | ▲ +17.2% |
| 2017 | 1.05x | CN¥273.64 Million | CN¥260.34 Million | ▲ +26.0% |
| 2016 | 0.83x | CN¥212.55 Million | CN¥254.87 Million | ▼ -24.4% |
| 2015 | 1.10x | CN¥231.01 Million | CN¥209.42 Million | ▲ +4.1% |
| 2014 | 1.06x | CN¥206.85 Million | CN¥195.28 Million | ▲ +4.2% |
| 2013 | 1.02x | CN¥111.36 Million | CN¥109.57 Million | ▲ +80.6% |
| 2012 | 0.56x | CN¥90.19 Million | CN¥160.24 Million | ▼ -32.6% |
| 2011 | 0.83x | CN¥87.01 Million | CN¥104.26 Million | ▼ -24.9% |
| 2010 | 1.11x | CN¥63.91 Million | CN¥57.50 Million | ▼ -7.2% |
| 2009 | 1.20x | CN¥42.37 Million | CN¥35.36 Million | ▲ +21.2% |
| 2008 | 0.99x | CN¥16.23 Million | CN¥16.42 Million | — |